Welcome to our dedicated page for Stevanato Group S P A SEC filings (Ticker: STVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stevanato Group S.p.A. (NYSE: STVN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including interim reports on Form 6-K and related exhibits. As a foreign private issuer, Stevanato Group uses Form 6-K to furnish unaudited interim condensed consolidated financial statements, management discussion and analysis, conference call scripts, and investor presentations.
In these filings, investors can review detailed revenue and margin information by segment for the Biopharmaceutical and Diagnostic Solutions and Engineering businesses, along with data on cost of sales, operating profit, finance income and expense, income taxes, and net profit. The interim reports also present information on property, plant and equipment, capital expenditures, cash flows, and net debt, helping readers understand the company’s investment and financing profile.
Stevanato Group’s 6-K filings include cautionary statements regarding forward-looking information and extensive risk factor discussions. These sections address topics such as product quality, technological change, competition, supply chain conditions, tariffs, geopolitical events, regulatory requirements, intellectual property, cybersecurity, and internal controls. The company also explains its use of non-GAAP measures, including EBITDA, Adjusted EBITDA, Adjusted Operating Profit, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt), and Capital Employed, and provides reconciliations in accompanying materials.
Through this page, users can follow real-time updates from EDGAR as new Stevanato Group filings are posted, including earnings-related 6-Ks, conference call scripts, and investor presentations. Stock Titan’s AI-powered tools summarize key points from lengthy documents, highlight important trends in revenue, margins, and capital investments, and make it easier to interpret complex tables and disclosures.
For those researching STVN, this filings archive offers a structured view of Stevanato Group’s financial reporting, risk disclosures, and strategic commentary, directly sourced from its official SEC submissions.
Neuberger Berman Group LLC and related entities report passive ownership of common shares of Stevanato Group S.p.A. under a Schedule 13G/A. Neuberger Berman Group LLC reports beneficial ownership of 4,960,362 shares, representing 10.0% of Stevanato’s common stock, with shared voting power over 4,725,907 shares and shared dispositive power over the full 4,960,362 shares as of the event date. Neuberger Berman Investment Advisers LLC reports beneficial ownership of 4,806,300 shares, or 9.7% of the class, with shared voting and dispositive powers over those shares.
The filing explains that these shares are held across various client and fiduciary accounts, and Neuberger Berman entities disclaim economic ownership, noting that clients retain the right to dividends and sale proceeds. The certification states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Stevanato Group.
Stevanato Group S.p.A. reported unaudited Q3 and nine‑month 2025 results showing higher sales and profitability. Q3 revenue was €303.2 million (up from €277.9 million), with operating profit of €52.7 million and net profit of €36.1 million; basic EPS was €0.13 (vs €0.11). Nine‑month revenue reached €839.8 million (vs €773.4 million), operating profit €128.7 million, and net profit €92.3 million.
Growth was led by the Biopharmaceutical and Diagnostic Solutions segment (Q3 €266.7 million), including a step‑up in high‑value solutions (€147.9 million vs €100.4 million). The Engineering segment posted €36.4 million. Cash from operations strengthened to €192.0 million year‑to‑date, while capex of €187.7 million supported the ramp‑up of the Fishers (U.S.) and Latina (Italy) sites. The company entered a rent‑to‑buy agreement for its Zhangjiagang, China facility and reported cash of €113.3 million at period end.
The effective tax rate improved to 25.2% for the nine months, reflecting Italy’s one‑year “IRES premiale” benefit. Net foreign exchange effects were a loss of €14.0 million year‑to‑date. One customer represented 12.6% of nine‑month revenue.
Artisan Partners reported beneficial ownership of 2,733,782 ordinary shares of Stevanato Group S.p.A., representing 5.5% of the class based on 49,604,649 shares outstanding as of 06/12/2025. The filing shows shared voting power of 2,316,046 and shared dispositive power over 2,733,782 shares, with no sole voting or dispositive power reported. The shares were acquired for discretionary clients of Artisan Partners Limited Partnership and the filers certify the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control.